In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report), with a ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics (PTGX – Research ...

JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target lifted by analysts at JPMorgan Chase & Co. from $51.00 to $53.00 in a research note issued to investors on ...

John Hussman Reduces Stake in Barrick Gold Corp by 68%, Impacting Portfolio by -2.11% ...

Truist Securities reiterated its Buy rating and $60.00 price target for Protagonist Therapeutics (NASDAQ:PTGX) shares, which currently trade at $38.78 with a market capitalization of $2.3 billion. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced that it has initiated a phase II study to evaluate its novel hepcidin mimetic candidate, PTG-300, in patients with... Puma Biotechnology ...

Protagonist Pictures will launch Stan Original rom-com 'One More Shot' for international sales at this year's European Film ...